TM Capital. Success. Realized. | Immucor Completes Debt Restructuring

Immucor, Inc. (NASDAQ: BLUD) is a leading supplier of diagnostic reagents and automated instrumentation to ensure the safety of blood transfusions
TM Capital was retained by Immucor to assist in restructuring indebtedness following covenant defaults on Immucor’s $42 million credit facility
TM Capital assisted Immucor in negotiating a restructuring agreement which waived all defaults, eliminated a potential going concern qualification and minimized financing costs

$41,925,000 Financial Restructuring

$15,500,000 Revolving Credit Facility $26,425,000 Term Loan

TM Capital assisted Immucor, Inc. (NASDAQ) in restructuring $42 million of senior indebtedness

For more information, contact our healthcare team at:

”

Immucor Completes Debt Restructuring